Zydus Launches India’s First Indigenously Developed Aflibercept
By Business Desk
Zydus Lifesciences launches Anyra, India’s first indigenously developed Aflibercept biosimilar to treat wet AMD and diabetic macular edema affordably.
Zydus Lifesciences has introduced Anyra in India, giving patients a brand new local option for managing tricky vision issues. The launch brings India its very first indigenously developed biosimilar of Aflibercept.
Targeting Major Retinal Conditions
The newly launched medication focuses heavily on serious eye health challenges that impact many individuals across the country. Patients dealing with vision impairment now have a locally developed alternative designed specifically for these conditions.
The Core Uses for Patients
Here are the primary retinal conditions treated by this new medication:
Wet age-related macular degeneration is one of the main targets for the therapy. Diabetic macular edema is the other primary condition addressed by the medication. Both of these health issues are noted as leading causes of vision impairment.
Affordability and Domestic Innovation
Zydus aims to reduce the financial burden on patients by providing a more cost-effective alternative to existing treatments. The development and approval of Anyra highlight the company’s strong commitment to enhancing access to critical ophthalmic therapies through domestic innovation.